

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/283269 A1

(51) International Patent Classification:

C07D 491/02 (2006.01) C07D 491/04 (2006.01)
A61K 31/50 (2006.01) C07D 491/044 (2006.01)
C07D 491/048 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2022/036260

(22) International Filing Date:

06 July 2022 (06.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/218,504 06 July 2021 (06.07.2021) US


(71) Applicant: SHIH, Chuan [US/CN]; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City, 11571 (TW).

(72) Inventors: HSU, Tsu-An; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City, 11571 (TW). HSIEH, Hsing-Pang; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City, 11571 (TW). CHANG, Sue-Ming; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd., Nangang Dist., Taipei City, 11571 (TW).

(74) Agent: CANFIELD, Floyd; MUNCY, GEISSLER, OLDS & LOWE, P.C., 4000 Legato Rd., Suite 310, Fairfax, Virginia 22033 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: CRYSTALLINE FORMS OF (S, E)-4-(DIMETHYLAMINO)-N-(3-(4-(2-HYDROXY-1-PHENYLETHYLAMINO)-6-PHENYLFURO[2,3-D]PYRIMIDIN-5-YL)PHENYL)BUT-2-ENAMIDE FREE BASE



(57) Abstract: Disclosed herein is a specific crystalline forms of (S, E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenylethylamino)-6-phenylfuro[2,3-d]pyrimidin-5-yl)phenyl)but-2-enamide (ABT-101) free base, the pharmaceutical composition and capsule comprising the same, and the medical application thereof. Said crystalline forms of ABT-101 free base can exhibit unexpected stability and improved pharmacokinetic properties compared to other forms or salt thereof, thereby allowing said compound more suitable for drug development and satisfying the requirements for bioavailability and drug efficacy.

[Continued on next page]

WO 2023/283269 A1

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))